47 completed, 13 active not recruiting, 12 terminated, 5 recruiting. 54 Phase 2, 40 Phase 1, 3 Phase 3.
Follow Selumetinib: new trials by email Literature Review of Selumetinib trials Research Report on Selumetinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2025-08-27 | 2026-05-29 |
| Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children Selumetinib - Plexiform Neurofibromas (PN) | Phase 2 | Not yet recruiting | West China Hospital | 50 | 2025-01-01 | 2025-01-08 |
| The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule Selumetinib - Neurofibromatosis 1 | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 19 | 2024-09-30 | 2024-10-01 |
| Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule Selumetinib - Neurofibromatosis 1 | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 33 | 2024-09-30 | 2024-10-01 |
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study Selumetinib, Placebo - Neurofibromatosis Type 1, Plexiform Neurofibromas | Phase 2 | Withdrawn | AstraZeneca | 2023-08-31 | 2023-08-14 | |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Selumetinib, Placebo - Neurofibromatosis 1, Plexiform Neurofibroma (PN) | Phase 3 | Active not recruiting | AstraZeneca | 145 | 2021-11-19 | 2026-11-12 |
| Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas Selumetinib - Neurofibromatosis Type 1 | Phase 1 | Active not recruiting | AstraZeneca | 24 | 2021-07-21 | 2026-08-20 |
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Selumetinib - Neurofibromatosis 1, Neurofibroma Plexiform | Phase 1 | Active not recruiting | AstraZeneca | 32 | 2020-12-16 | 2026-08-18 |
| Selumetinib Paediatric NF1 Japan Study Selumetinib - Neurofibromatosis Type 1 | Phase 1 | Completed | AstraZeneca | 12 | 2020-08-31 | 2023-04-26 |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Selumetinib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 21 | 2019-10-02 | 2026-05-27 |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 14 | 2019-09-26 | 2024-04-04 |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) Osimertinib, Savolitinib, Gefitinib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 247 | 2019-06-25 | 2025-01-30 |
| Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer Durvalumab, Selumetinib, Tremelimumab - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2019-04-01 | 2026-10-23 |
| Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) Selumetinib, Pembrolizumab - Advanced/Metastatic Solid Tumors | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 32 | 2019-03-18 | 2024-11-07 |
| Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) MK-8353, Selumetinib - Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 30 | 2019-02-22 | 2023-07-27 |
| AMTEC IIT: Phase 2 Multiarm Study in TNBC Biopsy, Capivasertib, Ceralasertib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Terminated | Gordon Mills, MD, PhD | 24 | 2018-12-12 | 2026-02-25 |
| Selumetinib and Azacitidine in High Risk Chronic Blood Cancers Azacitidine, Selumetinib - Chronic Myeloid Leukemia, Myelofibroses | Phase 1 | Recruiting | University of Chicago | 18 | 2018-09-04 | 2025-12-29 |
Showing 20 of 87. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (15) · Neurofibromatosis 1 (14) · Neurofibroma, Plexiform (8) · Melanoma (6) · Breast Neoplasms (5) · Colorectal Neoplasms (4) · Lung Neoplasms (4) · Pancreatic Neoplasms (4) · Biliary Tract Neoplasms (3) · Carcinoma, Hepatocellular (3) · Gallbladder Neoplasms (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Bile Duct Neoplasms (2) · Ependymoma (2)
National Cancer Institute (NCI) (27) · AstraZeneca (24) · M.D. Anderson Cancer Center (4) · Merck Sharp & Dohme LLC (3) · Canadian Cancer Trials Group (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · UNICANCER (2) · University of Birmingham (2) · Academic and Community Cancer Research United (1) · AeRang Kim (1) · Beijing Tiantan Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · Dana-Farber Cancer Institute (1) · Gordon Mills, MD, PhD (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1)
United States (55) · United Kingdom (17) · Canada (12) · France (9) · Spain (8) · Italy (6) · Netherlands (6) · Brazil (5) · China (4) · Denmark (4) · Germany (4) · Japan (4) · Poland (4) · Sweden (4) · Belgium (3)
AeRang Kim, MD, PhD (2) · Gabriella Mariani, MD (2) · Paul Chapman (2) · Tanios Bekaii-Saab (2) · Zhiquan Huang, doctoral (2) · Alan Ho, M.D., PHD (1) · Alan L Ho (1) · Alice P. Chen, MD (1) · Andrew Ko (1) · Arun Rajan, M.D. (1) · Barbara Lynn Melosky (1) · Bert O'Neil (1) · Birgit Geoerger, MD (1)
PMID 15683544, PMID 17105749, PMID 21996156, PMID 22353803, PMID 26851632, PMID 28029918, PMID 28230061, PMID 28409229, PMID 31010905, PMID 31582003, PMID 32187457, PMID 32379297, PMID 33354735, PMID 33863389, PMID 34541874, PMID 21519026, PMID 23077008, PMID 23200175, PMID 23261356, PMID 23735514, PMID 24178622, PMID 24938562, PMID 25516890, PMID 25667274, PMID 25887099, PMID 25892646, PMID 26028668, PMID 26125448, PMID 26410619, PMID 26837474, PMID 26912134, PMID 27751676, PMID 27921276, PMID 27978579, PMID 28492898, PMID 29718344, PMID 30317534, PMID 31151904, PMID 31200828, PMID 31538815, PMID 32027845, PMID 32067679, PMID 32203306, PMID 32669708, PMID 33536190, PMID 33748440, PMID 33892407, PMID 34347542, PMID 34389237, PMID 34543871
N01CM62208 (5), N01CM00070 (3), N01CM00071 (3), N01CM00100 (3), N01CM62201 (3), N01CM62206 (3), P30CA076292 (3), 2014 (2), 2016 (2), N01CM62207 (2), P30CA008748 (2), P30CA015083 (2), U10CA027469 (2), U10CA180868 (2), UM1CA186686 (2)